Akari Therapeutics has reaffirmed its commitment to advancing research on PH1, a novel spliceosome modulator payload used in its antibody drug conjugates (ADCs), which may offer a new approach to treating cancers driven by oncogenic mutations. PH1 modulates RNA splicing
read more
Collaboration aims to advance next-generation therapeutics and vaccines More: Kling Bio partners with Sanofi to accelerate antibody discovery Source: News
read moreHHS Secretary Robert F. Kennedy Jr. has signed off on a recommendation from an advisory committee to remove the preservative thimerosal from all flu shots distributed in the United States. More: RFK Jr. rubber-stamps ACIP recommendation to remove thimerosal from
read moreThe FDA was set to decide on GSK’s proposed Blenrep combinations in multiple myeloma by July 23. Instead, the agency is now extending its review through October 23. More: FDA delays Blenrep decision, putting GSK's multiple myeloma comeback dreams on
read moreAhead of the 10-year anniversary of Tagrisso’s original FDA approval this fall, AstraZeneca has debuted the first direct-to-consumer commercial for the lung cancer med. More: 10 years of Tagrisso: AstraZeneca unveils first TV ad for lung cancer treatment Source: fierce
read more
First patient dosed in phase 1b/2a study of procizumab More: 4TEEN4 begins trial of antibody therapy for cardiogenic shock Source: News
read more© 1994 - 2025 B.M. Pharmaceuticals